Pharmaceutical Investing NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia
Fortune Minerals Reports Successful NICO Project Bismuth Test Work Results for the Planned Alberta Refinery
